Calgary, AB, November 20, 2000 --- Oncolytics Biotech Inc (TSE:ONC)
Dr. Brad Thompson, President & Chief Executive Officer of Oncolytics Biotech Inc. (TSE:ONC) hosted a conference call today to explain the significance and impact of the company's licensing agreement for veterinary use with Pfizer Inc. announced earlier today.
There is a post-view facility, featuring a recording of the conference call available from 10:30 am Calgary time on Monday, November 20 through to end of business on Friday, November 25, 2000 by dialing 1-800-408-3053 and using the following access code 610017#
This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements.
Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas Read More
Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer Read More
Exploring REOLYSIN®’s Objective Response Rate in Females with Colorectal Cancer Read More
Sorry, there was a problem. Twitter returned the following error message:
Could not authenticate you.